AJCC staging system can be categorized as:

• A. Broad with longitudinal stability.
• B. Only capturing data at one point in time.
• C. Categories that rarely change.
• D. Forward flexibility and clinical utility.

Answer: (D)

The AJCC staging system is designed to be both adaptable and practically useful in guiding care. It uses the TNM framework to quantify tumor size/extent (T), nodal involvement (N), and distant metastasis (M), and it is periodically revised as new clinical and research data become available. This ongoing updates allow the system to reflect current understanding of prognosis and treatment impact, while still providing a standardized way to stratify patients across institutions. This combination—the ability to evolve with new evidence (forward flexibility) and its direct relevance to treatment decisions, prognosis, and trial eligibility (clinical utility)—is why it best fits the description. The other options don’t capture this dynamic, practice-oriented feature, since the system isn’t truly static, limited to a single time point, or inherently resistant to change.